Prospective Study to Validate the Imaging Biomarker for NCP (R33)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byPedram Hamrah, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Tufts Medical Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

The aim of this study is establish the reliability and clinical utility of microneuromas as identified via in vivo confocal microscopy as the diagnostic biomarker for NCP.

Research Team

Pedram Hamrah, MD

Principal Investigator

Tufts Medical Center

Eligibility Criteria

Inclusion Criteria

18 years of age or older

Ability to consent

Best corrected visual acuity of 20/40 or better in each eye

See 7 more

Treatment Details

Interventions

Microneuromas (Imaging Biomarker)

Participant Groups

3Treatment groups

Experimental Treatment

Group I: Neuropathic Corneal Pain GroupExperimental Treatment1 Intervention

Symptoms of ocular surface discomfort or pain for at least 3 months, that are reported to have a significant impact on quality of life and ability to perform daily activities.

Group II: Dry Eye Disease GroupExperimental Treatment1 Intervention

Symptoms of ocular surface discomfort or dry eye disease for at least 3 months, supported by clinical exam findings. Reported quality of life is not effected by ocular pain.

Group III: Control GroupExperimental Treatment1 Intervention

No symptoms of ocular surface discomfort or dry eye disease.